QXQingfeng Xu

Qingfeng Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingfeng Xu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Sen Bai

    Radiation Physics Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China

    2 shared publications
  • Yongmei Liu

    Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • You Lu

    Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Youling Gong

    Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China

    2 shared publications
  • Chang-Jin Sun

    Department of Radiation Oncology, Second People’s Hospital of Sichuan, Chengdu, 610031, P.R. China

    1 shared publication
  • Jin Wang

    Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects

    by Weijie Xiong, Qingfeng Xu, Yong Xu, Changjin Sun, Na Li, Lin Zhou, Yongmei Liu, Xiaojuan Zhou, Yongsheng Wang, Jin Wang, et al.

    Stereotactic body radiation therapy (SBRT) has emerged as an alternative treatment for patients with early stage non-small cell lung cancer (NSCLC) or metastatic pulmonary tumors. However, for isolated lung metastasis (ILM) of thoracic malignances after pulmonary lobectomy, reported outcomes of SBRT have been limited. This study evaluates the role of SBRT in the treatment of such patients. A retrospective search of the SBRT database was conducted in three hospitals. The parameters analyzed in the treated patients were local control, progression-free survival (PFS), overall survival (OS), and the treatment-related side-effects. In total, 23 patients with single ILM after pulmonary lobectomy treated with SBRT were identified and the median follow-up time was 14 months (range: 6.0-47.0 months). Local recurrences were observed in two patients during follow-up and the 1-year local control rate was 91.3%. Median PFS and OS for the studied cohort were 10.0 months [95% confidence interval (CI) 5.1-14.9 months] and 21.0 months (95% CI 11.4-30.6 months), respectively. Acute radiation pneumonitis (RP) of grade 2 or worse was observed in five (21.7%) and three (13.0%) patients, respectively. Other treatment-related toxicities included chest wall pain in one patient (4.3%) and acute esophagitis in two patients (8.7%). By Pearson correlation analysis, the planning target volume (PTV) volume and the volume of the ipsilateral lung exposed to a minimum dose of 5 Gy (IpV5) were significantly related to the acute RP of grade 2 or worse in present study (p < 0.05). The optimal thresholds of the PTV and IpV5 to predict RP of acute grade 2 or worse RP were 59 cm3 and 51% respectively, according to the receiver-operating characteristics curve analysis, with sensitivity/specificity of 75.0%/80.0% and 62.5%/80.0%. SBRT for post-lobectomy ILM was effective and well tolerated. The major reason for disease progression was distant failure but not local recurrence. The PTV and IpV5 are potential predictors of acute RP of grade 2 or higher and should be considered in treatment planning for such patients.


  • Open Access

    Dosimetric comparison using different multileaf collimeters in intensity-modulated radiotherapy for upper thoracic esophageal cancer

    by Youling Gong, Shichao Wang, Lin Zhou, Yongmei Liu, Yong Xu, You Lu, Sen Bai, Yuchuan Fu, Qingfeng Xu, Qingfeng Jiang

    Purpose: To study the impacts of multileaf collimators (MLC) width [standard MLC width of 10 mm (sMLC) and micro-MLC width of 4 mm (mMLC)] in the intensity-modulated radiotherapy (IMRT) planning for the upper thoracic esophageal cancer (UTEC). Methods and materials: 10 patients with UTEC were retrospectively planned with the sMLC and the mMLC. The monitor unites (MUs) and dose volume histogram-based parameters [conformity index (CI) and homogeneous index (HI)] were compared between the IMRT plans with sMLC and with mMLC. Results: The IMRT plans with the mMLC were more efficient (average MUs: 703.1 ± 68.3) than plans with the sMLC (average MUs: 833.4 ± 73.8) (p < 0.05). Also, compared to plans with the sMLC, the plans with the mMLC showed advantages in dose coverage of the planning gross tumor volume (Pgtv) (CI 0.706 ± 0.056/HI 1.093 ± 0.021) and the planning target volume (PTV) (CI 0.707 ± 0.029/HI 1.315 ± 0.013) (p < 0.05). In addition, the significant dose sparing in the D5 (3260.3 ± 374.0 vs 3404.5 ± 374.4)/gEUD (1815.1 ± 281.7 vs 1849.2 ± 297.6) of the spinal cord, the V10 (33.2 ± 6.5 vs 34.0 ± 6.7), V20 (16.0 ± 4.6 vs 16.6 ± 4.7), MLD (866.2 ± 174.1 vs 887.9 ± 172.1) and gEUD (938.6 ± 175.2 vs 956.8 ± 171.0) of the lungs were observed in the plans with the mMLC, respectively (p < 0.05). Conclusions: Comparing to the sMLC, the mMLC not only demonstrated higher efficiencies and more optimal target coverage, but also considerably improved the dose sparing of OARs in the IMRT planning for UTEC.